Actively Recruiting
Cardiac Injury Due to Anthracycline in Paediatric Oncological Patients
Led by IRCCS Burlo Garofolo · Updated on 2025-05-09
22
Participants Needed
1
Research Sites
521 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study investigates the role of echocardiography and of serum biomarkers (NT-proBNP, cardiac Troponin-I) in predicting cardiac injury in a cohort of paediatric oncological patients treated with Anthracycline chemotherapy.
CONDITIONS
Official Title
Cardiac Injury Due to Anthracycline in Paediatric Oncological Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pediatric oncological patients aged 0 to 18 years
- Planned start of Anthracycline chemotherapy
- Normal left ventricular systolic function according to International Guidelines before Anthracycline treatment
You will not qualify if you...
- Previous Anthracycline treatment, bone marrow transplantation, or chest radiation
- Echocardiographic evidence before Anthracycline treatment of more than mild pericardial effusion
- Echocardiographic evidence before Anthracycline treatment of more than mild mitral regurgitation
- Poor echocardiographic acoustic window
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
IRCCS Burlo Garofolo
Trieste, Italy, Italy, 34137
Actively Recruiting
Research Team
T
Thomas Caiffa, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here